BioLife Solutions
BLFS Β· Health Care Supplies
β
οΏ½οΏ½Envista
NVST Β· Health Care Supplies
$23.60
1.5%The short version
- Envista is the larger business, with $2.7B of revenue in fiscal 2025 against $96.2M for BioLife Solutions, about 28 times as much.
- BioLife Solutions grew revenue faster (28.9%, against 8.3%).
- Envista kept more of each dollar of sales as operating profit (8.0% operating margin, against β17.3% operating margin).
- BioLife Solutions turned more of its sales into free cash flow (11.1% FCF margin, against 8.5% FCF margin).
- Envista earned a higher return on the capital invested in it (3.2%, against β4.8%).
| Latest fiscal year | BLFS Β· FY25 | NVST Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $3.9B |
| Revenue | $96.2M | $2.7B |
| Free cash flow | $10.6M | $230M |
| Net income | β$4.6M | $47.0M |
| Growth | ||
| Revenue growth | 28.9% | 8.3% |
| 5-year growth | 14.9% | 7.1% |
| Share count change | 5.6% | β1.7% |
| Profitability | ||
| Gross margin | 64.6% | 54.7% |
| Operating margin | β17.3% | 8.0% |
| Net margin | β4.8% | 1.7% |
| FCF margin | 11.1% | 8.5% |
| Return on capital | β4.8% | 3.2% |
| Return on equity | β1.3% | 1.6% |
| Balance sheet | ||
| Net debt | β$83.9M | $237M |
| Net debt / EBITDA | β | 0.7x |
| Dividends and buybacks | $0.0M | $167M |
| Valuation & quality | ||
| P/E | β | 40.7x |
| Piotroski F-score | 6 | 7 |
FY16
BLFS $8.2M
NVST β
FY17
BLFS $11.0M
NVST $2.8B
FY18
BLFS $19.7M
NVST $2.8B
FY19
BLFS $27.4M
NVST $2.3B
FY20
BLFS $48.1M
NVST $1.9B
FY21
BLFS $119M
NVST $2.5B
FY22
BLFS $76.2M
NVST $2.6B
FY23
BLFS $68.0M
NVST $2.6B
FY24
BLFS $74.6M
NVST $2.5B
FY25
BLFS $96.2M
NVST $2.7B
BLFS
NVST
FY16
BLFS β59.0%
NVST β
FY17
BLFS β9.6%
NVST 13.8%
FY18
BLFS 18.6%
NVST 10.5%
FY19
BLFS β0.8%
NVST 10.3%
FY20
BLFS β13.0%
NVST 2.3%
FY21
BLFS β29.5%
NVST 12.2%
FY22
BLFS β7.8%
NVST 12.4%
FY23
BLFS β25.3%
NVST 1.2%
FY24
BLFS β6.0%
NVST β41.4%
FY25
BLFS β17.3%
NVST 8.0%
BLFS
NVST
FY16
BLFS β$4.5M
NVST β
FY17
BLFS $0.5M
NVST $310M
FY18
BLFS $1.9M
NVST $328M
FY19
BLFS $0.5M
NVST $320M
FY20
BLFS $4.7M
NVST $236M
FY21
BLFS β$13.0M
NVST $307M
FY22
BLFS β$18.9M
NVST $107M
FY23
BLFS β$18.9M
NVST $218M
FY24
BLFS $5.2M
NVST $303M
FY25
BLFS $10.6M
NVST $230M
BLFS
NVST
FY16
BLFS β
NVST β
FY17
BLFS β
NVST β
FY18
BLFS β
NVST β
FY19
BLFS β
NVST 3.9%
FY20
BLFS β6.5%
NVST 0.7%
FY21
BLFS β10.5%
NVST 6.0%
FY22
BLFS β1.3%
NVST 5.2%
FY23
BLFS β4.2%
NVST 0.5%
FY24
BLFS β1.2%
NVST β19.9%
FY25
BLFS β4.8%
NVST 3.2%
BLFS
NVST
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.